Skip to main content

Peer Review reports

From: Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial

Original Submission
18 Jul 2019 Submitted Original manuscript
6 Oct 2019 Reviewed Reviewer Report - Marcus Vetter
13 Nov 2019 Author responded Author comments - Shuo Wu
11 Dec 2019 Reviewed Reviewer Report - Benjamin Kasenda
6 Jan 2020 Author responded Author comments - Shuo Wu
Resubmission - Version 2
13 Nov 2019 Submitted Manuscript version 2
16 Jan 2020 Reviewed Reviewer Report - Benjamin Kasenda
11 Feb 2020 Author responded Author comments - Shuo Wu
Resubmission - Version 3
11 Feb 2020 Submitted Manuscript version 3
19 Feb 2020 Reviewed Reviewer Report - Christina Easter
4 Mar 2020 Author responded Author comments - Shuo Wu
Resubmission - Version 4
4 Mar 2020 Submitted Manuscript version 4
23 Mar 2020 Reviewed Reviewer Report - Christina Easter
7 Apr 2020 Author responded Author comments - Shuo Wu
Resubmission - Version 5
7 Apr 2020 Submitted Manuscript version 5
Publishing
24 Apr 2020 Editorially accepted
24 May 2020 Article published 10.1186/s13063-020-04342-x

You can find further information about peer review here.

Back to article page